{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=L-PLUS+meter", "query": { "intervention": "L-PLUS meter" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-04T01:32:04.815Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00409188", "title": "Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Tecemotide (L-BLP25)", "type": "BIOLOGICAL" }, { "name": "Single low dose cyclophosphamide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1513, "start_date": "2007-01", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2015-11-20", "last_synced_at": "2026-09-04T01:32:04.815Z", "location_count": 49, "location_summary": "Fort Smith, Arkansas • Anaheim, California • Glendale, California + 41 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00409188" }, { "nct_id": "NCT04033315", "title": "Performance of the L-PLUS BGMS by Persons With Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "L-PLUS meter", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Ascensia Diabetes Care", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2019-07-15", "completion_date": "2019-09-05", "has_results": true, "last_update_posted_date": "2024-06-13", "last_synced_at": "2026-09-04T01:32:04.815Z", "location_count": 1, "location_summary": "Renton, Washington", "locations": [ { "city": "Renton", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04033315" }, { "nct_id": "NCT02049151", "title": "Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Tecemotide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cyclophosphamide (CPA)", "type": "DRUG" }, { "name": "Saline (sodium chloride)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2014-03", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2017-08-23", "last_synced_at": "2026-09-04T01:32:04.815Z", "location_count": 1, "location_summary": "Rockland, Massachusetts", "locations": [ { "city": "Rockland", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02049151" }, { "nct_id": "NCT05104567", "title": "A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oesophageal Squamous Cell Carcinoma", "Gastric Cancer", "Hepatocellular Carcinoma", "Colorectal Cancer", "Oesophageal Adenocarcinoma" ], "interventions": [ { "name": "THOR-707", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2021-12-09", "completion_date": "2024-09-09", "has_results": true, "last_update_posted_date": "2025-09-24", "last_synced_at": "2026-09-04T01:32:04.815Z", "location_count": 3, "location_summary": "Duarte, California • Orlando, Florida • Seattle, Washington", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05104567" }, { "nct_id": "NCT04589845", "title": "Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Entrectinib", "type": "DRUG" }, { "name": "Alectinib", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Trastuzumab emtansine", "type": "DRUG" }, { "name": "Inavolisib", "type": "DRUG" }, { "name": "Belvarafenib", "type": "DRUG" }, { "name": "Pralsetinib", "type": "DRUG" }, { "name": "Divarasib", "type": "DRUG" }, { "name": "Camonsertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 920, "start_date": "2021-01-18", "completion_date": "2032-09-25", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-09-04T01:32:04.815Z", "location_count": 32, "location_summary": "Goodyear, Arizona • Los Angeles, California • Newport Beach, California + 25 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04589845" }, { "nct_id": "NCT03390504", "title": "A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urothelial Cancer" ], "interventions": [ { "name": "Erdafitinib", "type": "DRUG" }, { "name": "Vinflunine", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 629, "start_date": "2018-03-23", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-09-04T01:32:04.815Z", "location_count": 26, "location_summary": "Anchorage, Alaska • Sacramento, California • St. Helena, California + 22 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Sacramento", "state": "California" }, { "city": "St. Helena", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03390504" }, { "nct_id": "NCT01652482", "title": "Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "MEHD7945A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2012-10", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-04T01:32:04.815Z", "location_count": 19, "location_summary": "Bakersfield, California • Fullerton, California • Los Angeles, California + 14 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Luis Obispo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01652482" }, { "nct_id": "NCT01496131", "title": "Tecemotide (L-BLP25) in Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Radiation therapy", "type": "RADIATION" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Tecemotide (L-BLP25)", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 28, "start_date": "2011-10-24", "completion_date": "2016-11-25", "has_results": true, "last_update_posted_date": "2018-03-09", "last_synced_at": "2026-09-04T01:32:04.815Z", "location_count": 1, "location_summary": "Rockland, Massachusetts", "locations": [ { "city": "Rockland", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01496131" }, { "nct_id": "NCT01339494", "title": "Nitric Oxide Production in MELAS Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "MELAS Syndrome" ], "interventions": [ { "name": "Arginine and citrulline supplementations", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "3 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "3 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2009-07", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2016-04-05", "last_synced_at": "2026-09-04T01:32:04.815Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01339494" }, { "nct_id": "NCT00925548", "title": "STRIDE - STimulating Immune Response In aDvanced brEast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Tecemotide (L-BLP25) and Hormonal Treatment", "type": "BIOLOGICAL" }, { "name": "Placebo of tecemotide (L-BLP25) and Hormonal Treatment", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "sodium chloride (NaCl)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 16, "start_date": "2009-09", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2014-07-24", "last_synced_at": "2026-09-04T01:32:04.815Z", "location_count": 1, "location_summary": "Hickory, North Carolina", "locations": [ { "city": "Hickory", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00925548" } ] }